These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 26303895)
1. Design, synthesis, pharmacological characterization of a fluorescent agonist of the P2Y₁₄ receptor. Kiselev E; Balasubramanian R; Uliassi E; Brown KA; Trujillo K; Katritch V; Hammes E; Stevens RC; Harden TK; Jacobson KA Bioorg Med Chem Lett; 2015 Nov; 25(21):4733-4739. PubMed ID: 26303895 [TBL] [Abstract][Full Text] [Related]
2. Exploring a 2-naphthoic acid template for the structure-based design of P2Y14 receptor antagonist molecular probes. Kiselev E; Barrett MO; Katritch V; Paoletta S; Weitzer CD; Brown KA; Hammes E; Yin AL; Zhao Q; Stevens RC; Harden TK; Jacobson KA ACS Chem Biol; 2014 Dec; 9(12):2833-42. PubMed ID: 25299434 [TBL] [Abstract][Full Text] [Related]
3. Molecular modeling of the human P2Y14 receptor: A template for structure-based design of selective agonist ligands. Trujillo K; Paoletta S; Kiselev E; Jacobson KA Bioorg Med Chem; 2015 Jul; 23(14):4056-64. PubMed ID: 25868749 [TBL] [Abstract][Full Text] [Related]
4. Recent progress on the discovery of P2Y Lu R; Zhang Z; Jiang C Eur J Med Chem; 2019 Aug; 175():34-39. PubMed ID: 31071548 [TBL] [Abstract][Full Text] [Related]
5. Tools and drugs for uracil nucleotide-activated P2Y receptors. Rafehi M; Müller CE Pharmacol Ther; 2018 Oct; 190():24-80. PubMed ID: 29660366 [TBL] [Abstract][Full Text] [Related]
6. Structure-Based Design of 3-(4-Aryl-1H-1,2,3-triazol-1-yl)-Biphenyl Derivatives as P2Y14 Receptor Antagonists. Junker A; Balasubramanian R; Ciancetta A; Uliassi E; Kiselev E; Martiriggiano C; Trujillo K; Mtchedlidze G; Birdwell L; Brown KA; Harden TK; Jacobson KA J Med Chem; 2016 Jul; 59(13):6149-68. PubMed ID: 27331270 [TBL] [Abstract][Full Text] [Related]
7. UDP-sugars activate P2Y Abbas ZSB; Latif ML; Dovlatova N; Fox SC; Heptinstall S; Dunn WR; Ralevic V Vascul Pharmacol; 2018 Apr; 103-105():36-46. PubMed ID: 29253618 [TBL] [Abstract][Full Text] [Related]
8. A selective high-affinity antagonist of the P2Y14 receptor inhibits UDP-glucose-stimulated chemotaxis of human neutrophils. Barrett MO; Sesma JI; Ball CB; Jayasekara PS; Jacobson KA; Lazarowski ER; Harden TK Mol Pharmacol; 2013 Jul; 84(1):41-9. PubMed ID: 23592514 [TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationships of pyrimidine nucleotides containing a 5'-α,β-methylene diphosphonate at the P2Y Oliva P; Scortichini M; Dobelmann C; Jain S; Gopinatth V; Toti KS; Phung NB; Junker A; Jacobson KA Bioorg Med Chem Lett; 2021 Aug; 45():128137. PubMed ID: 34048882 [TBL] [Abstract][Full Text] [Related]
10. P2-pyrimidinergic receptors and their ligands. Müller CE Curr Pharm Des; 2002; 8(26):2353-69. PubMed ID: 12369950 [TBL] [Abstract][Full Text] [Related]
11. Discovery and computational studies of 2-phenyl-benzoxazole acetamide derivatives as promising P2Y Zhou M; Wang W; Wang Z; Wang Y; Zhu Y; Lin Z; Tian S; Huang Y; Hu Q; Li H Eur J Med Chem; 2022 Jan; 227():113933. PubMed ID: 34689072 [TBL] [Abstract][Full Text] [Related]
12. Human P2Y(14) receptor agonists: truncation of the hexose moiety of uridine-5'-diphosphoglucose and its replacement with alkyl and aryl groups. Das A; Ko H; Burianek LE; Barrett MO; Harden TK; Jacobson KA J Med Chem; 2010 Jan; 53(1):471-80. PubMed ID: 19902968 [TBL] [Abstract][Full Text] [Related]
13. Lighting up G protein-coupled purinergic receptors with engineered fluorescent ligands. Ciruela F; Fernández-Dueñas V; Jacobson KA Neuropharmacology; 2015 Nov; 98():58-67. PubMed ID: 25890205 [TBL] [Abstract][Full Text] [Related]
14. UDP-glucose sensing P2Y Zhang JZ; Shi NR; Wu JS; Wang X; Illes P; Tang Y Neuropharmacology; 2023 Nov; 238():109655. PubMed ID: 37423482 [TBL] [Abstract][Full Text] [Related]
15. Breakthrough in GPCR Crystallography and Its Impact on Computer-Aided Drug Design. Ciancetta A; Jacobson KA Methods Mol Biol; 2018; 1705():45-72. PubMed ID: 29188558 [TBL] [Abstract][Full Text] [Related]
16. Functional characterization of purinergic receptor P2Y Li S; Wang N; Feng Y; Li J; Geng X; Sun J Fish Shellfish Immunol; 2019 Oct; 93():200-207. PubMed ID: 31326587 [TBL] [Abstract][Full Text] [Related]
17. John Daly Lecture: Structure-guided Drug Design for Adenosine and P2Y Receptors. Jacobson KA; Gao ZG; Paoletta S; Kiselev E; Chakraborty S; Jayasekara PS; Balasubramanian R; Tosh DK Comput Struct Biotechnol J; 2015; 13():286-98. PubMed ID: 25973142 [TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationship of uridine 5'-diphosphoglucose analogues as agonists of the human P2Y14 receptor. Ko H; Fricks I; Ivanov AA; Harden TK; Jacobson KA J Med Chem; 2007 May; 50(9):2030-9. PubMed ID: 17407275 [TBL] [Abstract][Full Text] [Related]
19. Enhanced potency of nucleotide-dendrimer conjugates as agonists of the P2Y14 receptor: multivalent effect in G protein-coupled receptor recognition. Das A; Zhou Y; Ivanov AA; Carter RL; Harden TK; Jacobson KA Bioconjug Chem; 2009 Aug; 20(8):1650-9. PubMed ID: 19572637 [TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and anti-inflammatory evaluation of 3-amide benzoic acid derivatives as novel P2Y Zhang Z; Hao K; Li H; Lu R; Liu C; Zhou M; Li B; Meng Z; Hu Q; Jiang C Eur J Med Chem; 2019 Nov; 181():111564. PubMed ID: 31376563 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]